Generation of functional, antigen-specific CD81 human T cells from cord blood stem cells using exogenous notch and tetramer-TCR signaling

Stem Cells

Volumn 32, Issue 1, 2014, Pages 93-104

  Fernandez, Irina ^a,b   Ooi, Tracy P ^a,c   Roy, Krishnendu ^a,c  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Adult hematopoietic stem cells; CD34+ cells; Cytotoxic T cells; Human cord blood

Indexed keywords

CD34 ANTIGEN; CD7 ANTIGEN; EPITOPE; GAMMA INTERFERON; GRANZYME B; HLA A ANTIGEN; INTERLEUKIN 2; LIGAND; NOTCH RECEPTOR; T LYMPHOCYTE RECEPTOR; T6 ANTIGEN; TETRAMER;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME RELEASE; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; TARGET CELL; UMBILICAL CORD BLOOD;

ADULT HEMATOPOIETIC STEM CELLS; CD34+ CELLS; CYTOTOXIC T CELLS; HUMAN CORD BLOOD;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA; FETAL BLOOD; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HLA-A2 ANTIGEN; HUMANS; MICE; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84891752647     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1512     Document Type: Article

References (50)

1. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol 2002;2:309-322.
2. Laky K, Fleischacker C, Fowlkes BJ. TCR and Notch signaling in CD4 and CD8 T-cell development. Immunol Rev 2006;209:274-283.
3. Dudley ME, Wunderlich J, Nishimura MI et al. Adoptive transfer of cloned melanomareactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-373.
4. Dudley ME, Rosenberg S. Adoptive-celltransfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3: 666-675.
5. Gong MC, Latouche JB, Krause A et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999;1:123-127.
6. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007;117:1204-1210.
7. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105: 3051-3057.
8. Plautz GE, Bukowski RM, Novick AC et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 1999;54: 617-623.
9. Rosenberg SA, Restifo NP, Yang JC et al. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
10. Awong G, Herer E, La Motte-Mohs RN et al. Human CD8 T cells generated in vitro from hematopoietic stem cells are functionally mature. BMC Immunol 2011;12.
11. Holmes R, Zuniga-Pflücker JC. The OP9-DL1 system: Generation of T-lymphocytes from embryonic or hematopoietic stem cells in vitro. Cold Spring Harb Protoc 2009;2.
12. La Motte-Mohs RN, Herer E, Zuniga-Pflücker JC. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 2005;105: 1431-1439.
13. Schmitt TM, Zuniga-Pflücker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002;17:749-756.
14. Dallas MH, Varnum-Finney B, Delaney C et al. Density of notch ligand Delta1 determines generation of B and T cell precursors from hematopoietic stem cells. J Exp Med 2005;201:1361-1366.
15. Dallas MH, Varnum-Finney B, Martin PJ et al. Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1. Blood 2007; 109:3579-3587.
16. Delaney C, Varnum-Finney B, Aoyama K et al. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 2005;106:2693-2699.
17. Varnum-Finney B, Wu L, Yu M et al. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci 2000;113:4313-4318.
18. Taqvi S, Dixit L, Roy K. Biomaterial-based notch signaling for the differentiation of hematopoietic stem cells into T cells. J Biomed Mater Res A 2006;79:689-697.
19. Dervovic DD, Ciofani M, Kianizad K et al. Comparative and functional evaluation of in vitro generated ex vivo CD8 T cells. J Immunol 2012;189:3411-3420.
20. Lin J, Nie H, Tucker PW et al. Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD81 T cells from embryonic stem cells and thymic progenitors. Tissue Eng Part A 2010;16:2709-2720.
21. Zhao Y, Parkhurst M, Zheng Z et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res 2007;67:2425-2429.
22. van Lent AU, Nagasawa M, van Loenen MM et al. Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol 2007;179:4959-4968.
23. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigenspecific CD81 T cells by a flow cytometric assay for degranulation. J Immunol Methods 2008;281:65-78.
24. Karanu FN, Murdoch B, Miyabayashi T et al. Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood 2001;97:1960-1967.
25. Lacey SF, Martinez J, Gallez-Hawkins G et al. Simultaneous reconstitution of multiple cytomegalovirus-specific CD81 cell populations with divergent functionality in hematopoietic stem-cell transplant recipients. J Infect Dis 2005;191:977-984.
26. Mittendorf EA, Storrer CE, Shriver CD et al. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD81 cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat 2005;92:85-93.
27. Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003;9: 1377-1382.
28. Trapani JA, Smyth MJ. Functional significant of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002;2:735-747.
29. Emerson SG. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapeutics. Blood 1996;87:3082-3088.
30. Flores-Guzman P, Gutierrez-Rodriguez M, Mayani H. In vitro proliferation, expansion, and differentiation of a CD341 cell-enriched hematopoietic cell population from umbilical cord blood in response to recombinant cytokines. Arch Med Res 2002;33:107-114.
31. Opelz G, Wujciak T, Döhler B. Is HLA matching worth the effort? Collaborative Transplant Study. Transplant Proc 1999;31: 717-720.
32. Bart T. Cost effectiveness of cord blood versus bone marrow and peripheral blood stem cells. Clinicoecon Outcomes Res 2010;2: 141-147.
33. Zuniga-Pflücker J. T-cell development made simple. Nat Rev Immunol 2004;4:67-72.
34. Shah DK, Mohtashami M, Zuniga-Pflücker JC. Role of recycling, Mindbomb1 association, and exclusion from lipid rafts of Delta-like 4 for effective Notch signaling to drive T cell development. J Immunol 2012; 189:5797-5808.
35. Heuss SF, Ndiaye-Lobry D, Six EM et al. The intracellular region of Notch ligands Dll1 and Dll3 regulates their trafficking and signaling activity. Proc Natl Acad Sci USA 2008; 105:11212-11217.
36. von Essen MR, Kongsbak M, Geisler C. Mechanisms behind functional avidity maturation in T cells. Clin Dev Immunol 2012; 2012:163453.
37. Bluestone JA. New perspectives of CD28-B7 mediated T cell costimulation. Immunity 1995;2:555-559.
38. Boesteanu AC, Katsikis PD. Memory T cells need CD28 costimulation to remember. Semin Immunol 2009;21:69-77.
39. Sagerstrom CG, Kerr EM, Allison JP et al. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci USA 1993;90:8987-8991.
40. Wagner DH Jr. Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for bad. Clin Immunol 2007;123:1-6.
41. Ali M, Weinreich M, Balcaitis S et al. Differential regulation of peripheral CD41 T cell tolerance induced by deletion and TCR revision. J Immunol 2003;171:6290-6296.
42. Hale JS, Ames KT, Boursalian TE et al. Cutting Edge: Rag deletion in peripheral T cells blocks TCR revision. J Immunol 2010; 184:5964-5968.
43. McMahan CJ, Fink PJ. RAG reexpression and DNA recombination at T cell receptor loci in peripheral CD41 T cells. Immunity 1998;9:637-647.
44. McMahan CJ, Fink PJ. Receptor revision in peripheral T cells creates a diverse Vbeta repertoire. J Immunol 2000;165:6902-6907.
45. Lantleme E, Orlando L, Porcedda P et al. An in vitro model of T cell receptor revision in mature human CD81 T cells. Mol Immunol 2008;45:328-337.
46. Durum SK, Candeias S, Nakajima H et al. Interleukin 7 receptor control of T cell receptor gamma gene rearrangement: Role of receptor-associated chains and locus accessibility. J Exp Med 1998;188:2233-2241.
47. Huang J, Muegge K. Control of chromatin accessibility for V(D)J recombination by interleukin-7. J Leukoc Biol 2001;69:907-911.
48. Muegge K, Vila MP, Durum SK. Interleukin-7: A cofactor for V(D)J rearrangement of the T cell receptor beta gene. Science 1993; 261:93-95.
49. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigenspecific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20:143-148.
50. Savage P, Millrain M, Diimakou S et al. Expansion of CD81 cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumour Biol 2007;28:70-76.